Wanbangde Pharmaceutical (SHE:002082) obtained drug registration with China's medical products regulator for its sulpiride tablets.
The drug is for schizophrenia treatment with additional antidepressant, antiemetic, and gastric secretion inhibitory effects, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 10% higher Tuesday.